Moderna has started a late-stage U.S. and UK trial of its experimental bird flu vaccine, marking the first mRNA-based pandemic bird flu vaccine to reach Phase 3 testing. The update is a meaningful development for Moderna’s pipeline and supports the company’s vaccine platform, though it is still an early commercialization step. The news is likely to modestly influence Moderna shares and sentiment across the vaccine/biotech group.
Moderna has started a late-stage U.S. and UK trial of its experimental bird flu vaccine, marking the first mRNA-based pandemic bird flu vaccine to reach Phase 3 testing. The update is a meaningful development for Moderna’s pipeline and supports the company’s vaccine platform, though it is still an early commercialization step. The news is likely to modestly influence Moderna shares and sentiment across the vaccine/biotech group.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
